Idarucizumab
ATC V03AB37 · 10 markets · 11 records
Idarucizumab
Forms
AU 2 records · 2 strengths
- 2,500 mginjectionPRAXBIND idarucizumab (rch) 50 mg/ml solution for injection/infusion vial
Records without a stated strength · 1 Praxbind
US 1 records · 1 strengths
- 50 mginjectionPraxbind
GB 1 records · 1 strengths
- 2,500 mg/50 mLinjectionPraxbind 2.5g/50ml solution for infusion vials
CA 1 records · 1 strengths
- 50 mgliquidPraxbind
SG 1 records · 1 strengths
- 50 mg/mLinjectionPRAXBIND SOLUTION FOR INJECTION/INFUSION 50 MG/ML
ES 1 records · 1 strengths
- 50 mg/1 mLinjectionPraxbind
TW 1 records · 1 strengths
Records without a stated strength · 1 Praxbind Solution for injection/infusion、達栓普注射液/輸注液
HK 1 records · 1 strengths
Records without a stated strength · 1 Praxbind Solution for injection/infusion
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 Praxbind
The same ingredient can carry completely different
brand names in different countries, and the same name can point to a different ingredient.
Listed by country — not interchangeable.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.
A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.